Cost analysis of different brands of antianginal drugs available in India

Authors

  • L. Akila Department of Pharmacology, SRM Medical College Hospital & Research Centre, SRM University, Potheri, Kattankulathur, Kanchipuram, Tamil Nadu
  • R. Jamuna Rani Department of Pharmacology, SRM Medical College Hospital & Research Centre, SRM University, Potheri, Kattankulathur, Kanchipuram, Tamil Nadu

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20150856

Keywords:

Antianginal drugs, Cost analysis, Branded drugs

Abstract

Background: Ischemic heart diseaseis the most common cardiovascular disease in developed countries such as United States and Angina pectoris is the most frequent among them. If not managed adequately angina results in significant morbidity and mortality too due to the complications. Antianginal therapy is lifelong. Therefore, analysis of the price of drugs used in ischemic heart disease will help to improve patient compliance.

Methods: Prices of various antianginal drugs of different strengths and combinations marketed by different companies was obtained from current index of medical stores. The variation between highest and lowest price of the same medication manufactured by various pharma companies and percentage variation in price for ten tablets was calculated.

Results: In India, percentage variation in price for antianginal drugs was found to be: tablet isosorbide dinitrate (5 mg) 250%, glyceryltrinitrate (6.4 mg) 24.44%.

In calcium channel blockers group, tablet amlodipine 10 mg shows maximum price variation of 1045%, closely followed by 5 mg of amlodipine with a variation of 1040%, while 120 mg of diltiazem shows the least variation of 262%. In beta-adrenergic receptor blockers group, tablet atenolol 50 mg shows maximum price variation of 563%, whereas 100 mg of extended release metoprolol shows the least variation of 42%.

Conclusions: To increase the benefit to the patient and reduce drug in compliance, doctors should be trained to be familiar from internship period itself about the brand names of cost-effective drugs with good safety profile for a long period.

References

Chauhan S, Aeri BT. Prevalence of cardiovascular disease in India and it is economic impact - A review. Int J Sci Res Publ. 2013;3(10):2-4.

Michel T, Hoffman BB. Treatment of myocardial ischemia and hypertension. In: Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 11th Edition. New York, NY: McGraw-Hill; 2005: 745.

Buxton IL. Principles of prescription order writing and patient compliance. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 11th Edition. New York, NY: McGraw-Hill; 2005: 1886.

Lofholm PW, Katzung BG. Rational prescribing and prescription writing. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th Edition. New Delhi: Tata McGraw-Hill Education Private Limited; 2009.

Satoskar RS, Bhandarkar SD, Rege NN. In pharmacotherapy of angina pectoris, acute mi and peripheral vascular diseases. Pharmacology and Pharmacotherapeutics. Revised 23rd Edition. New Delhi: Elsevier; 2013: 401.

Ritter J, Lewis L, Mant T, Ferro A. In: a Textbook of Clinical Pharmacology and Therapeutics. 5th Edition. London:A Hodder Arnold Publication; 2012: 196-203.

Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008;62(2):338-51.

Indian Brand Equity Foundation. Introduction: Indian Pharmaceutical Industry. Available at http://www.ibef.org/industry/pharmaceutical-india.aspx. Accessed 01 August 2015.

Patel BJ, Patel KH, Patel MP. Antidepressant drugs: evaluation of price variation. Int J Basic Clin Pharmacol. 2015;4(3):432-7.

Kheder SI, Ali HM. Evaluating medicines prices, availability, affordability and price components in Sudan. Sudan Med Monit. 2014;9(1):19.

Karve AV, Chattar KB. Cost analysis study of oral antihypertensive agents available in Indian market. Int J Basic Clin Pharmacol. 2014;3(3):479-83.

Patel KP, Joshi HM, Khandhedia C, Shah H, Shah KN, Patel VJ. Study of drug utilization, morbidity pattern and cost of hypolipidemic agents in a tertiary care hospital. Int J Basic Clin Pharmacol. 2013;2(4):470-5.

Date AP, Mahajan HM, Dashputra AV, Bhosale RR. Study of variation in price of various antidiabetic drugs available in Indian market. Int J Basic Clin Pharmacol. 2015;4(1):36-40.

Downloads

Published

2016-12-23

How to Cite

Akila, L., & Rani, R. J. (2016). Cost analysis of different brands of antianginal drugs available in India. International Journal of Basic & Clinical Pharmacology, 4(5), 860–863. https://doi.org/10.18203/2319-2003.ijbcp20150856

Issue

Section

Original Research Articles